Literature DB >> 17145787

Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.

Gabriel Birkus1, Ruth Wang, Xiaohong Liu, Nilima Kutty, Holly MacArthur, Tomas Cihlar, Craig Gibbs, Swami Swaminathan, William Lee, Martin McDermott.   

Abstract

GS-7340 and GS-9131 {9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]-propyl]adenine and 9-(R)-4'-(R)-[[[(S)-1-[(ethoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]-2'-fluoro-1'-furanyladenine, respectively} are novel alkylalaninyl phenyl ester prodrugs of tenofovir {9-R-[(2-phosphonomethoxy)propyl]adenine} (TFV) and a cyclic nucleotide analog, GS-9148 (phosphonomethoxy-2'-fluoro-2', 3'-dideoxydidehydroadenosine), respectively. Both prodrugs exhibit potent antiretroviral activity against both wild-type and drug-resistant human immunodeficiency virus type 1 strains and excellent in vivo pharmacokinetic properties. In this study, the main enzymatic activity responsible for the initial step in the intracellular activation of GS-7340 and GS-9131 was isolated from human peripheral blood mononuclear cells and identified as lysosomal carboxypeptidase A (cathepsin A [CatA]; EC 3.4.16.5). Biochemical properties of the purified hydrolase (native complex and catalytic subunit molecular masses of 100 and 29 kDa, respectively; isoelectric point [pI] of 5.5) matched those of CatA. Recombinant CatA and the isolated prodrug hydrolase displayed identical susceptibilities to inhibitors and identical substrate preferences towards a panel of tenofovir phosphonoamidate prodrugs. Incubation of both enzymes with 14C-labeled GS-7340 or [3H]difluorophosphonate resulted in the covalent labeling of identical 29-kDa catalytic subunits. Finally, following a 4-h incubation with GS-7340 and GS-9131, the intracellular concentrations of prodrug metabolites detected in CatA-negative fibroblasts were approximately 7.5- and 3-fold lower, respectively, than those detected in normal control fibroblasts. Collectively, these data demonstrate the key role of CatA in the intracellular activation of nucleotide phosphonoamidate prodrugs and open new possibilities for further improvement of this important class of antiviral prodrugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145787      PMCID: PMC1797775          DOI: 10.1128/AAC.00968-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  46 in total

1.  Activity-based protein profiling: the serine hydrolases.

Authors:  Y Liu; M P Patricelli; B F Cravatt
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 2.  Lysosomal multienzyme complex: biochemistry, genetics, and molecular pathophysiology.

Authors:  A V Pshezhetsky; M Ashmarina
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  2001

3.  Human lysosomal beta-galactosidase-cathepsin A complex: definition of the beta-galactosidase-binding interface on cathepsin A.

Authors:  A V Pshezhetsky; M A Elsliger; M V Vinogradova; M Potier
Journal:  Biochemistry       Date:  1995-02-28       Impact factor: 3.162

4.  Human monocyte carboxylesterase. Purification and kinetics.

Authors:  A M Saboori; D S Newcombe
Journal:  J Biol Chem       Date:  1990-11-15       Impact factor: 5.157

5.  Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.

Authors:  William A Lee; Gong-Xin He; Eugene Eisenberg; Tomas Cihlar; Swami Swaminathan; Andrew Mulato; Kenneth C Cundy
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

Review 6.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

7.  Human lysosomal protective protein. Glycosylation, intracellular transport, and association with beta-galactosidase in the endoplasmic reticulum.

Authors:  H Morreau; N J Galjart; R Willemsen; N Gillemans; X Y Zhou; A d'Azzo
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

8.  A novel serine esterase expressed by cytotoxic T lymphocytes.

Authors:  M S Pasternack; H N Eisen
Journal:  Nature       Date:  1985 Apr 25-May 1       Impact factor: 49.962

9.  Human placental neuraminidase. Activation, stabilization and association with beta-galactosidase and its protective protein.

Authors:  F W Verheijen; S Palmeri; A T Hoogeveen; H Galjaard
Journal:  Eur J Biochem       Date:  1985-06-03

10.  Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages.

Authors:  H L Jackman; F Tan; D Schraufnagel; T Dragović; B Dezsö; R P Becker; E G Erdös
Journal:  Am J Respir Cell Mol Biol       Date:  1995-08       Impact factor: 6.914

View more
  52 in total

1.  Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy.

Authors:  Eisuke Murakami; Ting Wang; Yeojin Park; Jia Hao; Eve-Irene Lepist; Darius Babusis; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

Review 2.  Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.

Authors:  William R Lykins; Ellen Luecke; Daniel Johengen; Ariane van der Straten; Tejal A Desai
Journal:  Drug Deliv Transl Res       Date:  2017-12       Impact factor: 4.617

3.  Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.

Authors:  Andrew J Ocque; Colleen E Hagler; Gene D Morse; Scott L Letendre; Qing Ma
Journal:  J Pharm Biomed Anal       Date:  2018-04-23       Impact factor: 3.935

Review 4.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier.

Authors:  Andrew J Wiemer; David F Wiemer
Journal:  Top Curr Chem       Date:  2015

5.  Design and Synthesis of Fluorescent Acyclic Nucleoside Phosphonates as Potent Inhibitors of Bacterial Adenylate Cyclases.

Authors:  Petra Břehová; Markéta Šmídková; Jan Skácel; Martin Dračínský; Helena Mertlíková-Kaiserová; Monica P Soto Velasquez; Val J Watts; Zlatko Janeba
Journal:  ChemMedChem       Date:  2016-10-24       Impact factor: 3.466

Review 6.  Synthesis of nucleoside phosphate and phosphonate prodrugs.

Authors:  Ugo Pradere; Ethel C Garnier-Amblard; Steven J Coats; Franck Amblard; Raymond F Schinazi
Journal:  Chem Rev       Date:  2014-08-21       Impact factor: 60.622

7.  Metabolism and pharmacokinetics of the anti-hepatitis C virus nucleotide prodrug GS-6620.

Authors:  Eisuke Murakami; Ting Wang; Darius Babusis; Eve-Irene Lepist; Dorothea Sauer; Yeojin Park; Jennifer E Vela; Robert Shih; Gabriel Birkus; Dimitrios Stefanidis; Choung U Kim; Aesop Cho; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

8.  Synthesis of a long acting nanoformulated emtricitabine ProTide.

Authors:  Dhruvkumar Soni; Aditya N Bade; Nagsen Gautam; Jonathan Herskovitz; Ibrahim M Ibrahim; Nathan Smith; Melinda S Wojtkiewicz; Bhagya Laxmi Dyavar Shetty; Yazen Alnouti; JoEllyn McMillan; Howard E Gendelman; Benson J Edagwa
Journal:  Biomaterials       Date:  2019-08-20       Impact factor: 12.479

9.  In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.

Authors:  Christian Callebaut; George Stepan; Yang Tian; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

10.  A Cyclic Phosphoramidate Prodrug of 2'-Deoxy-2'-Fluoro-2'-C-Methylguanosine for the Treatment of Dengue Virus Infection.

Authors:  Ratna Karuna; Fumiaki Yokokawa; Keshi Wang; Jin Zhang; Haoying Xu; Gang Wang; Mei Ding; Wai Ling Chan; Nahdiyah Abdul Ghafar; Andrea Leonardi; Cheah Chen Seh; Peck Gee Seah; Wei Liu; Rao P S Srinivasa; Siew Pheng Lim; Suresh B Lakshminarayana; Ellie Growcott; Sreehari Babu; Martijn Fenaux; Weidong Zhong; Feng Gu; Pei-Yong Shi; Francesca Blasco; Yen-Liang Chen
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.